Glycoprotein 41 - Pipeline Review, H1 2020

May 2020 | 66 pages | ID: G87B62BF9813EN
Global Markets Direct

Abstracts

Glycoprotein 41 - Pipeline Review, H1 2020

SUMMARY

Glycoprotein 41 (gp41) – Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

The latest report Glycoprotein 41 – Pipeline Review, H1 2020, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
• The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
• The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) - Overview
Glycoprotein 41 (gp41) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Glycoprotein 41 (gp41) - Drug Profiles
albuvirtide LAR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human immunodeficiency virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) - Dormant Products
Glycoprotein 41 (gp41) - Discontinued Products
Glycoprotein 41 (gp41) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Frontier Biotechnologies Inc, H1 2020
Pipeline by Longevity Biotech Inc, H1 2020
Pipeline by Minka Therapeutics SA, H1 2020
Pipeline by Molecular Express Inc, H1 2020
Pipeline by Mymetics Corp, H1 2020
Pipeline by Navigen Inc, H1 2020
Pipeline by Novodux, H1 2020
Pipeline by Osel Inc, H1 2020
Pipeline by Protheragen Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc